Institutional Corruption and the Pharmaceutical Policy

Lessig L. , Republic, Lost: How Money Corrupts Congress – and a Plan to Stop It (New York: Twelve, 2011); Thompson D. F. , Ethics in Congress: From Individual to Institutional Corruption (Washington, D.C.: The Brookings Institution, 1995); Thompson D. F. , “Two Concepts of Corruption: Making Campaigns Safe for Democracy,” George Washington Law Review 73, no. 5 & 6 (2005): 1036–1069. For other work related to institutional corruption, see the web page of the Lab at the Safra Edmond J. Center for Ethics, which has links to working papers, blogs, and information about research of Lab Fellows: <http://www.ethics.harvard.edu/lab> (last visited July 29, 2013).

Jorgensen P. D. , “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 553–555.

Gagnon M.-A. , “Corruption of Pharmaceutical Markets: Addressing the Misalignment of Financial Incentives and Public Health,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 571–580.

Rodwin M. A. , “Five Un-Easy Pieces to Pharmaceutical Policy Reform,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 581–589.

Light D. W. Lexchin J. Darrow J. J. , “Institutional Corruption of Pharmaceuticals and the Myth of Safe and Effective Drugs,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 590–600.

Miller J. E. , “From Bad Pharma to Good Pharma: Aligning Market Forces with Good and Trustworthy Practices through Accreditation, Certification, & Rating,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 601–610.

Brown A. , “Understanding Pharmaceutical Research Manipulation in the Context of Accounting Manipulation,” Journal of Law, Medicine, & Ethics 41, no. 3 (2013): 611–619.

Feldman Y. Gauthier R. Schuler T. , “Curbing Misconduct in the Pharmaceutical Industry: Insights from Behavioral Ethics and the Behavioral Approach to Law,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 620–628.

Gray G. C. , “The Ethics of Pharmaceutical Research Funding: A Social Organization Approach,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 629–634.

Sismondo S. , “Key Opinion Leaders and the Corruption of Medical Knowledge: What the Sunshine Act Will and Won't Cast Light On,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 635–643.

Cosgrove L. Wheeler E. , “Drug Firms, Codification of Diagnostic Categories and Bias in Clinical Guidelines,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 644–653.

Kassirer J. , On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health (Oxford University Press, 2005).

Rodwin M. A. , “Rooting Out Institutional Corruption to Manage Inappropriate Off-Label Drug Use,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 654–664.

Sah S. Fugh-Berman A. , “Physicians under the Influence: Social Psychology and Industry Marketing Strategies,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 665–672.

Landa A. S. Elliott C. , “From Community to Commodity: The Ethics of Pharma-Funded Social Networking Sites for Physicians,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 673–679.

Rodwin M. A. , “Patient Accountability and Quality of Care: Lessons from Medical Consumerism and the Patients' Rights, Women's Health and Disability Rights Movements,” American Journal of Law and Medicine 20, nos. 1 & 2 (1994): 147–167; Rodwin M. A. , “Exit and Voice in American Health Care,” Michigan Journal of Law Reform 32, no. 4 (1999): 1041–1067.

Rose S. L. , “Patient Advocacy Organizations: Institutional Conflicts of Interest, Trust, and Trustworthiness,” Journal of Law, Medicine & Ethics 41, no. 3 (2013): 680–687.

Jorgensen P. D. , “Pharmaceuticals, Political Money, and Public Policy: A Theoretical and Empirical Agenda,” Journal of Law, Medicine & Ethics 14, no. 3 (2013): 561–570.

See Light Lexchin Darrow , supra note 5.

See Rodwin , supra note 4.

See Sismondo , supra note 10.

See Brown , supra note 7.

See Gray , supra note 9.

See Cosgrove Wheeler , supra note 11.

See Sah Fugh-Berman , supra note 14.

See Landa Elliott , supra note 15.

See Rose , supra note 17.

See Light Lexchin Darrow , supra note 5; Gagnon , supra note 3; Rodwin , supra note 4.

See Rodwin , supra note 13.

See Brown , supra note 7.

See Feldman Gauthier Schuler , supra note 8.

See Miller , supra note 6.

See Sah Fugh-Berman , supra note 14.

See Sismondo , supra note 10.

See Rodwin , supra note 13.

See Landa Elliott , supra note 15.

See Gagnon , supra note 3.

See Light Lexchin Darrow , supra note 5

Rodwin M. A. , “Conflicts of Interest: The Limitations of Disclosure,” New England Journal of Medicine 321, no. 20 (1989): 1405–1408. See also, Rodwin M. A. , Medicine, Money and Morals: Physicians' Conflicts of Interest (New York: Oxford University Press, 1993): At 213–219; Rodwin M. A. , Conflicts of Interest and the Future of Medicine: The United States, France and Japan (New York: Oxford University Press, 2011): At 214–219.

See Sismondo , supra note 10.

See Cosgrove Wheeler , supra note 11.

See Feldman Gauthier Schuler , supra note 8.

See Rose , supra note 17.